{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:45:01Z","timestamp":1791953101962,"version":"4.3.4"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":285,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, autosomal dominant muscular dystrophy caused by a trinucleotide GCN repeat expansion in the\n                    <jats:italic>PABPN1<\/jats:italic>\n                    gene on chromosome 14q11.2. The disease is clinically characterised by progressive ptosis, dysphagia, and proximal limb weakness, with onset typically between the fifth and sixth decades. OPMD affects approximately 1:100,000 individuals in Europe, with substantially higher prevalence in specific founder populations, reaching 1:600 among Bukharan Jews and 1:1,000 in French Canadians. The expanded polyalanine tract in PABPN1 promotes protein misfolding and formation of tubulofilamentous intranuclear inclusions, the histopathological hallmark of the disease. Pathogenic mechanisms involve a complex interplay of gain-of-function toxicity from aggregated mutant PABPN1, loss-of-function effects due to reduced polyadenylation efficiency, and dominant-negative impairment of poly(A) tail elongation, mRNA processing and nuclear mRNA export. Recent advances in proximity proteomics have refined the understanding of how the alanine expansion destabilises PABPN1 and alters its interactome. Diagnosis relies on molecular genetic testing of the\n                    <jats:italic>PABPN1<\/jats:italic>\n                    GCN repeat expansion, while PABPN1 immunofluorescence on muscle biopsy provides a highly sensitive and specific ancillary tool. Current management remains symptomatic, including cricopharyngeal myotomy for dysphagia and surgical correction of ptosis. The therapeutic landscape is evolving, with BB-301, an adeno-associated virus-based gene therapy employing a DNA-directed RNA interference (ddRNAi) silence-and-replace strategy, currently in a Phase 1b\/2a clinical trial\n                    <jats:italic>.<\/jats:italic>\n                    This review provides a comprehensive synthesis of OPMD, spanning historical background, molecular genetics, pathophysiology, clinical presentation, diagnostic approach, and the emerging therapeutic pipeline.\n                  <\/jats:p>","DOI":"10.1007\/s12035-026-06251-7","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:59:33Z","timestamp":1791925173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oculopharyngeal Muscular Dystrophy: From Molecular Pathogenesis to Gene Therapy"],"prefix":"10.1007","volume":"63","author":[{"given":"Claudia","family":"Alberti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Gagliardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ripolone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Moggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo Pietro","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-969X","authenticated-orcid":false,"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"6251_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000072861","volume":"100","author":"B Brais","year":"2003","unstructured":"Brais B (2003) Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet Genome Res 100:252\u2013260. https:\/\/doi.org\/10.1159\/000072861","journal-title":"Cytogenet Genome Res"},{"key":"6251_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/00005053-191503000-00001","volume":"42","author":"EW Taylor","year":"1915","unstructured":"Taylor EW (1915) Progressive vagus-glossopharyngeal paralysis with ptosis: a contribution to the group of family diseases. J Nerv Ment Dis 42:129\u2013139","journal-title":"J Nerv Ment Dis"},{"key":"6251_CR3","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM196212202672501","volume":"267","author":"M Victor","year":"1962","unstructured":"Victor M, Hayes R, Adams RD (1962) Oculopharyngeal muscular dystrophy. A familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 267:1267\u20131272. https:\/\/doi.org\/10.1056\/NEJM196212202672501","journal-title":"N Engl J Med"},{"key":"6251_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/ng0298-164","volume":"18","author":"B Brais","year":"1998","unstructured":"Brais B, Bouchard JP, Xie YG, Rochefort DL, Chretien N, Tome FM, Lafreniere RG, Rommens JM, et al. (1998) Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 18:164\u2013167. https:\/\/doi.org\/10.1038\/ng0298-164","journal-title":"Nat Genet"},{"issue":"Suppl 1","key":"6251_CR5","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/s0960-8966(97)00080-1","volume":"7","author":"SC Blumen","year":"1997","unstructured":"Blumen SC, Nisipeanu P, Sadeh M, Asherov A, Blumen N, Wirguin Y, Khilkevich O, Carasso RL, et al. (1997) Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul Disord 7(Suppl 1):S38\u201340. https:\/\/doi.org\/10.1016\/s0960-8966(97)00080-1","journal-title":"Neuromuscul Disord"},{"key":"6251_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1212\/WNL.55.9.1267","volume":"55","author":"SC Blumen","year":"2000","unstructured":"Blumen SC, Korczyn AD, Lavoie H, Medynski S, Chapman J, Asherov A, Nisipeanu P, Inzelberg R, et al. (2000) Oculopharyngeal MD among Bukhara Jews is due to a founder (GCG)9 mutation in the PABP2 gene. Neurology 55:1267\u20131270. https:\/\/doi.org\/10.1212\/WNL.55.9.1267","journal-title":"Neurology"},{"key":"6251_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1055\/s-2008-1040826","volume":"19","author":"B Brais","year":"1999","unstructured":"Brais B, Rouleau GA, Bouchard JP, Fardeau M, Tome FM (1999) Oculopharyngeal muscular dystrophy. Semin Neurol 19:59\u201366. https:\/\/doi.org\/10.1055\/s-2008-1040826","journal-title":"Semin Neurol"},{"issue":"Suppl 1","key":"6251_CR8","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0960-8966(97)00077-1","volume":"7","author":"JP Bouchard","year":"1997","unstructured":"Bouchard JP, Brais B, Brunet D, Gould PV, Rouleau GA (1997) Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 7(Suppl 1):S22\u201329. https:\/\/doi.org\/10.1016\/S0960-8966(97)00077-1","journal-title":"Neuromuscul Disord"},{"key":"6251_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/ene.15252","volume":"29","author":"J Alonso-Perez","year":"2022","unstructured":"Alonso-Perez J, de Leon Hernandez JC, Perez-Perez H, Mendoza-Grimon MD, Gutierrez-Martinez AJ, Hadjigeorgiou I, Monton-Alvarez F, Gonzalez-Quereda L, et al. (2022) Clinical and genetic features of a large homogeneous cohort of oculopharyngeal muscular dystrophy patients from the Canary Islands. Eur J Neurol 29:1488\u20131495. https:\/\/doi.org\/10.1111\/ene.15252","journal-title":"Eur J Neurol"},{"key":"6251_CR10","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.286.19.2437","volume":"286","author":"MW Becher","year":"2001","unstructured":"Becher MW, Morrison L, Davis LE, Maki WC, King MK, Bicknell JM, Reinert BL, Bartolo C, et al. (2001) Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 286:2437\u20132440. https:\/\/doi.org\/10.1001\/jama.286.19.2437","journal-title":"JAMA"},{"key":"6251_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1136\/jim-2016-000184","volume":"65","author":"M Cruz-Aguilar","year":"2017","unstructured":"Cruz-Aguilar M, Guerrero-de Ferran C, Tovilla-Canales JL, Nava-Castaneda A, Zenteno JC (2017) Characterization of PABPN1 expansion mutations in a large cohort of Mexican patients with oculopharyngeal muscular dystrophy (OPMD). J Investig Med 65:705\u2013708. https:\/\/doi.org\/10.1136\/jim-2016-000184","journal-title":"J Investig Med"},{"key":"6251_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.nmd.2004.10.012","volume":"15","author":"M Rodriguez","year":"2005","unstructured":"Rodriguez M, Camejo C, Bertoni B, Braida C, Rodriguez MM, Brais B, Medici M, Roche L (2005) (GCG)11 founder mutation in the PABPN1 gene of OPMD Uruguayan families. Neuromuscul Disord 15:185\u2013190. https:\/\/doi.org\/10.1016\/j.nmd.2004.10.012","journal-title":"Neuromuscul Disord"},{"key":"6251_CR13","volume-title":"GeneReviews","author":"C Trollet","year":"2020","unstructured":"Trollet C, Boulinguiez A, Roth F, Stojkovic T, Butler-Browne G, Evangelista T, Lacau St Guily J, Richard P (2020) Oculopharyngeal muscular dystrophy. In: Adam MP, Bick S, Mirzaa GM et al (eds) GeneReviews. University of Washington, Seattle"},{"key":"6251_CR14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.7868\/S0016675816030097","volume":"52","author":"AV Marusin","year":"2016","unstructured":"Marusin AV, Kurtanov KhA, Maksimova NR, Svarovskaya MG, Stepanov VA (2016) Haplotype analysis of oculopharyngeal muscular dystrophy (OPMD) locus in Yakutia. Genetika 52:376\u2013384 (in Russian)","journal-title":"Genetika"},{"key":"6251_CR15","unstructured":"ClinicalTrials.gov (2026) A study of BB-301 in oculopharyngeal muscular dystrophy (OPMD). Identifier: NCT06185673. U.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/study\/NCT06185673. Accessed August 2026"},{"key":"6251_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF00692226","volume":"49","author":"FM Tome","year":"1980","unstructured":"Tome FM, Fardeau M (1980) Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol 49:85\u201387. https:\/\/doi.org\/10.1007\/BF00692226","journal-title":"Acta Neuropathol"},{"key":"6251_CR17","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/hmg\/4.3.429","volume":"4","author":"B Brais","year":"1995","unstructured":"Brais B, Xie YG, Sanson M, Morgan K, Weissenbach J, Korczyn AD, Blumen SC, Fardeau M, et al. (1995) The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 4:429\u2013434. https:\/\/doi.org\/10.1093\/hmg\/4.3.429","journal-title":"Hum Mol Genet"},{"key":"6251_CR18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1093\/oxfordjournals.hmg.a018924","volume":"9","author":"A Calado","year":"2000","unstructured":"Calado A, Tome FM, Brais B, Rouleau GA, Kuhn U, Wahle E, Carmo-Fonseca M (2000) Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum Mol Genet 9:2321\u20132328. https:\/\/doi.org\/10.1093\/oxfordjournals.hmg.a018924","journal-title":"Hum Mol Genet"},{"key":"6251_CR19","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1111\/febs.12294","volume":"280","author":"A Banerjee","year":"2013","unstructured":"Banerjee A, Apponi LH, Pavlath GK, Corbett AH (2013) PABPN1: molecular function and muscle disease. FEBS J 280:4230\u20134250. https:\/\/doi.org\/10.1111\/febs.12294","journal-title":"FEBS J"},{"key":"6251_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006418","volume":"4","author":"JP Tavanez","year":"2009","unstructured":"Tavanez JP, Bengoechea R, Berciano MT, Lafarga M, Carmo-Fonseca M, Enguita FJ (2009) Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE 4:e6418. https:\/\/doi.org\/10.1371\/journal.pone.0006418","journal-title":"PLoS ONE"},{"key":"6251_CR21","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/hmg\/ddp569","volume":"19","author":"LH Apponi","year":"2010","unstructured":"Apponi LH, Leung SW, Williams KR, Valentini SR, Corbett AH, Pavlath GK (2010) Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Hum Mol Genet 19:1058\u20131065. https:\/\/doi.org\/10.1093\/hmg\/ddp569","journal-title":"Hum Mol Genet"},{"key":"6251_CR22","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s12017-014-8327-5","volume":"16","author":"J Shan","year":"2014","unstructured":"Shan J, Chen B, Lin P, Li D, Luo Y, Ji K, Zheng J, Yuan Y, et al. (2014) Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a Chinese population. Neuromolecular Med 16:782\u2013786. https:\/\/doi.org\/10.1007\/s12017-014-8327-5","journal-title":"Neuromolecular Med"},{"key":"6251_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2005.037598","volume":"43","author":"DO Robinson","year":"2006","unstructured":"Robinson DO, Wills AJ, Hammans SR, Read SP, Sillibourne J (2006) Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation. J Med Genet 43:e23. https:\/\/doi.org\/10.1136\/jmg.2005.037598","journal-title":"J Med Genet"},{"issue":"1","key":"6251_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s12883-021-02300-x","volume":"21","author":"YS Nishii","year":"2021","unstructured":"Nishii YS, Noto YI, Yasuda R, Kitaoji T, Ashida S, Tanaka E, Minami N, Nishino I, et al. (2021) A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G>C; p.Gly12Ala point mutation. BMC Neurol 21(1):265. https:\/\/doi.org\/10.1186\/s12883-021-02300-x","journal-title":"BMC Neurol"},{"key":"6251_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JND-221669","volume":"10","author":"Y Takahashi","year":"2023","unstructured":"Takahashi Y, Morimoto N, Nada T, Morimoto M, Eura N, Minami N, Nishino I (2023) A case of oculopharyngeal muscular dystrophy caused by a novel PABPN1 c.34G>T (p.Gly12Trp) point mutation without polyalanine expansion. J Neuromuscul Dis 10:459\u2013463. https:\/\/doi.org\/10.3233\/JND-221669","journal-title":"J Neuromuscul Dis"},{"key":"6251_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00439-004-1235-2","volume":"116","author":"DO Robinson","year":"2005","unstructured":"Robinson DO, Hammans SR, Read SP, Sillibourne J (2005) Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism. Hum Genet 116:267\u2013271. https:\/\/doi.org\/10.1007\/s00439-004-1235-2","journal-title":"Hum Genet"},{"key":"6251_CR27","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1001\/archneur.59.3.474","volume":"59","author":"M Nakamoto","year":"2002","unstructured":"Nakamoto M, Nakano S, Kawashima S, Ihara M, Nishimura Y, Shinde A, Kakizuka A (2002) Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy. Arch Neurol 59:474\u2013477. https:\/\/doi.org\/10.1001\/archneur.59.3.474","journal-title":"Arch Neurol"},{"key":"6251_CR28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1212\/WNL.0000000000003554","volume":"88","author":"P Richard","year":"2017","unstructured":"Richard P, Trollet C, Stojkovic T, de Becdelievre A, Perie S, Pouget J, Eymard B, Neurologists of French Neuromuscular Reference Centers CORNEMUS and FILNEMUS (2017) Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy. Neurology 88:359\u2013365. https:\/\/doi.org\/10.1212\/WNL.0000000000003554","journal-title":"Neurology"},{"key":"6251_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.nmd.2006.11.009","volume":"17","author":"S Hebbar","year":"2007","unstructured":"Hebbar S, Webberley MJ, Lunt P, Robinson DO (2007) Siblings with recessive oculopharyngeal muscular dystrophy. Neuromuscul Disord 17:254\u2013257. https:\/\/doi.org\/10.1016\/j.nmd.2006.11.009","journal-title":"Neuromuscul Disord"},{"key":"6251_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3233\/JND-140060","volume":"2","author":"P Richard","year":"2015","unstructured":"Richard P, Trollet C, Gidaro T, Demay L, Brochier G, Malfatti E, Tome FMS, Fardeau M, et al. (2015) PABPN1 (GCN)11 as a dominant allele in oculopharyngeal muscular dystrophy: consequences in clinical diagnosis and genetic counselling. J Neuromuscul Dis 2:175\u2013180. https:\/\/doi.org\/10.3233\/JND-140060","journal-title":"J Neuromuscul Dis"},{"key":"6251_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO;2-O","volume":"46","author":"SC Blumen","year":"1999","unstructured":"Blumen SC, Brais B, Korczyn AD, Medinsky S, Chapman J, Asherov A, Nisipeanu P, Codere F, et al. (1999) Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 46:115\u2013118. https:\/\/doi.org\/10.1002\/1531-8249(199907)46:1%3c115::AID-ANA17%3e3.0.CO;2-O","journal-title":"Ann Neurol"},{"key":"6251_CR32","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1212\/WNL.0b013e3181b388a3","volume":"73","author":"SC Blumen","year":"2009","unstructured":"Blumen SC, Bouchard JP, Brais B, Carasso RL, Paleacu D, Drory VE, Chantal S, Blumen N, et al. (2009) Cognitive impairment and reduced life span of oculopharyngeal muscular dystrophy homozygotes. Neurology 73:596\u2013601. https:\/\/doi.org\/10.1212\/WNL.0b013e3181b388a3","journal-title":"Neurology"},{"key":"6251_CR33","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.gde.2005.04.003","volume":"15","author":"A Albrecht","year":"2005","unstructured":"Albrecht A, Mundlos S (2005) The other trinucleotide repeat: polyalanine expansion disorders. Curr Opin Genet Dev 15:285\u2013293. https:\/\/doi.org\/10.1016\/j.gde.2005.04.003","journal-title":"Curr Opin Genet Dev"},{"key":"6251_CR34","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1093\/hmg\/ddg329","volume":"12","author":"H Lavoie","year":"2003","unstructured":"Lavoie H, Debeane F, Trinh QD, Turcotte JF, Corbeil-Girard LP, Dicaire MJ, Saint-Denis A, Page M, et al. (2003) Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Hum Mol Genet 12:2967\u20132979. https:\/\/doi.org\/10.1093\/hmg\/ddg329","journal-title":"Hum Mol Genet"},{"key":"6251_CR35","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00401-022-02503-7","volume":"144","author":"F Roth","year":"2022","unstructured":"Roth F, Dhiab J, Boulinguiez A, Mouigni HR, Lassche S, Negroni E, Muraine L, Marhic A, et al. (2022) Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy. Acta Neuropathol 144:1157\u20131170. https:\/\/doi.org\/10.1007\/s00401-022-02503-7","journal-title":"Acta Neuropathol"},{"key":"6251_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1261\/rna.7217105","volume":"11","author":"JP Tavanez","year":"2005","unstructured":"Tavanez JP, Calado P, Braga J, Lafarga M, Carmo-Fonseca M (2005) In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 11:752\u2013762. https:\/\/doi.org\/10.1261\/rna.7217105","journal-title":"RNA"},{"key":"6251_CR37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.nbd.2011.12.052","volume":"46","author":"R Bengoechea","year":"2012","unstructured":"Bengoechea R, Tapia O, Casafont I, Berciano J, Lafarga M, Berciano MT (2012) Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy. Neurobiol Dis 46:118\u2013129. https:\/\/doi.org\/10.1016\/j.nbd.2011.12.052","journal-title":"Neurobiol Dis"},{"key":"6251_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/hmg\/ddh017","volume":"13","author":"H Hino","year":"2004","unstructured":"Hino H, Araki K, Uyama E, Takeya M, Araki M, Yoshinobu K, Miike K, Kawazoe Y, et al. (2004) Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum Mol Genet 13:181\u2013190. https:\/\/doi.org\/10.1093\/hmg\/ddh017","journal-title":"Hum Mol Genet"},{"key":"6251_CR39","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/hmg\/ddq098","volume":"19","author":"C Trollet","year":"2010","unstructured":"Trollet C, Anvar SY, Venema A, Hargreaves IP, Foster K, Vignaud A, Ferry A, Negroni E, et al. (2010) Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum Mol Genet 19:2191\u20132207. https:\/\/doi.org\/10.1093\/hmg\/ddq098","journal-title":"Hum Mol Genet"},{"key":"6251_CR40","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1038\/sj.emboj.7601117","volume":"25","author":"A Chartier","year":"2006","unstructured":"Chartier A, Benoit B, Simonelig M (2006) A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 25:2253\u20132262. https:\/\/doi.org\/10.1038\/sj.emboj.7601117","journal-title":"EMBO J"},{"key":"6251_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.cell.2012.03.022","volume":"149","author":"M Jenal","year":"2012","unstructured":"Jenal M, Elkon R, Loayza-Puch F, van Haaften G, Kuhn U, Menzies FM, Oude Vrielink JA, Bos AJ, et al. (2012) The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149:538\u2013553. https:\/\/doi.org\/10.1016\/j.cell.2012.03.022","journal-title":"Cell"},{"key":"6251_CR42","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fnagi.2014.00317","volume":"6","author":"Y Raz","year":"2014","unstructured":"Raz Y, Raz V (2014) Oculopharyngeal muscular dystrophy as a paradigm for muscle aging. Front Aging Neurosci 6:317. https:\/\/doi.org\/10.3389\/fnagi.2014.00317","journal-title":"Front Aging Neurosci"},{"key":"6251_CR43","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1093\/hmg\/ddx206","volume":"26","author":"KE Vest","year":"2017","unstructured":"Vest KE, Phillips BL, Banerjee A, Apponi LH, Dammer EB, Xu W, Zheng D, Yu J, et al. (2017) Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology. Hum Mol Genet 26:3235\u20133252. https:\/\/doi.org\/10.1093\/hmg\/ddx206","journal-title":"Hum Mol Genet"},{"key":"6251_CR44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1011743","volume":"22","author":"AT Mezzell","year":"2026","unstructured":"Mezzell AT, Zhang Y, Perez AM, Vest KE (2026) Oculopharyngeal muscular dystrophy (OPMD) associated alanine expansion impairs the function of the nuclear polyadenosine RNA binding protein PABPN1 as revealed by proximity labeling and comparative proteomics. PLoS Genet 22:e1011743. https:\/\/doi.org\/10.1371\/journal.pgen.1011743","journal-title":"PLoS Genet"},{"key":"6251_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.880141004","volume":"14","author":"R Pauzner","year":"1991","unstructured":"Pauzner R, Blatt I, Mouallem M, Ben-David E, Farfel Z, Sadeh M (1991) Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Muscle Nerve 14:947\u2013952. https:\/\/doi.org\/10.1002\/mus.880141004","journal-title":"Muscle Nerve"},{"key":"6251_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0022-510X(74)90067-7","volume":"21","author":"J Julien","year":"1974","unstructured":"Julien J, Vital C, Vallat JM, Vallat M, Le Blanc M (1974) Oculopharyngeal muscular dystrophy. A case with abnormal mitochondria and \u201cfingerprint\u201d inclusions. J Neurol Sci 21:165\u2013169. https:\/\/doi.org\/10.1016\/0022-510X(74)90067-7","journal-title":"J Neurol Sci"},{"key":"6251_CR47","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1002\/mus.880150911","volume":"15","author":"J Arenas","year":"1992","unstructured":"Arenas J, Huertas RA, Campos Y, Cabello A, Gutierrez E, Bautista J, Segura D (1992) Oculopharyngeal muscular dystrophy and mitochondrial abnormalities. Muscle Nerve 15:1055\u20131056. https:\/\/doi.org\/10.1002\/mus.880150911","journal-title":"Muscle Nerve"},{"key":"6251_CR48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0960-8966(95)00039-9","volume":"6","author":"KT Wong","year":"1996","unstructured":"Wong KT, Dick D, Anderson JR (1996) Mitochondrial abnormalities in oculopharyngeal muscular dystrophy. Neuromuscul Disord 6:163\u2013166. https:\/\/doi.org\/10.1016\/0960-8966(95)00039-9","journal-title":"Neuromuscul Disord"},{"key":"6251_CR49","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000077070","volume":"51","author":"S Gambelli","year":"2004","unstructured":"Gambelli S, Malandrini A, Ginanneschi F, Berti G, Cardaioli E, De Stefano R, Franci M, Salvadori C, et al. (2004) Mitochondrial abnormalities in genetically assessed oculopharyngeal muscular dystrophy. Eur Neurol 51:144\u2013147. https:\/\/doi.org\/10.1159\/000077070","journal-title":"Eur Neurol"},{"key":"6251_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005092","volume":"11","author":"A Chartier","year":"2015","unstructured":"Chartier A, Klein P, Pierson S, Barbezier N, Gidaro T, Casas F, Carberry S, Dowling P, et al. (2015) Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. PLoS Genet 11:e1005092. https:\/\/doi.org\/10.1371\/journal.pgen.1005092","journal-title":"PLoS Genet"},{"key":"6251_CR51","doi-asserted-by":"publisher","unstructured":"Shademan M, Flannery S, Bos E, Evers TMJ, Sheikhhassani V, Mashaghi A, Kusters B, van Engelen B, et al. (2026) Nuclear protein aggregates disrupt RNA processing and alter biomechanics in a muscle cell model of OPMD. Aging Dis 17:2583\u20132603. https:\/\/doi.org\/10.14336\/AD.2025.0699","DOI":"10.14336\/AD.2025.0699"},{"key":"6251_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/IOP.0000000000002118","volume":"38","author":"DR Jordan","year":"2022","unstructured":"Jordan DR, Klapper SR, Farmer J (2022) Oculopharyngeal muscular dystrophy ptosis, Mueller\u2019s muscle involvement, and a review of management over 34 years. Ophthalmic Plast Reconstr Surg 38:535\u2013542. https:\/\/doi.org\/10.1097\/IOP.0000000000002118","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"6251_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/mus.26888","volume":"62","author":"JD Brisson","year":"2020","unstructured":"Brisson JD, Gagnon C, Brais B, Cote I, Mathieu J (2020) A study of impairments in oculopharyngeal muscular dystrophy. Muscle Nerve 62:201\u2013207. https:\/\/doi.org\/10.1002\/mus.26888","journal-title":"Muscle Nerve"},{"key":"6251_CR54","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00415-011-6255-y","volume":"259","author":"R Dubbioso","year":"2012","unstructured":"Dubbioso R, Moretta P, Manganelli F, Fiorillo C, Iodice R, Trojano L, Santoro L (2012) Executive functions are impaired in heterozygote patients with oculopharyngeal muscular dystrophy. J Neurol 259:833\u2013837. https:\/\/doi.org\/10.1007\/s00415-011-6255-y","journal-title":"J Neurol"},{"key":"6251_CR55","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012640","volume":"97","author":"RHMJM Kroon","year":"2021","unstructured":"Kroon RHMJM, Kalf JG, de Swart BJM, van der Sluijs BM, Glennon JC, Raz V, van Engelen BG, Horlings CGC (2021) Longitudinal assessment of strength, functional capacity, oropharyngeal function, and quality of life in oculopharyngeal muscular dystrophy. Neurology 97:e1475-e1483. https:\/\/doi.org\/10.1212\/WNL.0000000000012640","journal-title":"Neurology"},{"key":"6251_CR56","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/ene.14131","volume":"27","author":"V Galimberti","year":"2020","unstructured":"Galimberti V, Tironi R, Lerario A, Scali M, Del Bo R, Rodolico C, Brizzi T, Gibertini S, et al. (2020) Value of insoluble PABPN1 accumulation in the diagnosis of oculopharyngeal muscular dystrophy. Eur J Neurol 27:709\u2013715. https:\/\/doi.org\/10.1111\/ene.14131","journal-title":"Eur J Neurol"},{"key":"6251_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s40478-022-01482-w","volume":"10","author":"M Ogasawara","year":"2022","unstructured":"Ogasawara M, Eura N, Iida A, Kumutpongpanich T, Minami N, Nonaka I, Hayashi S, Noguchi S, et al. (2022) Intranuclear inclusions in muscle biopsy can differentiate oculopharyngodistal myopathy and oculopharyngeal muscular dystrophy. Acta Neuropathol Commun 10:176. https:\/\/doi.org\/10.1186\/s40478-022-01482-w","journal-title":"Acta Neuropathol Commun"},{"key":"6251_CR58","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1016\/j.clinph.2015.03.005","volume":"126","author":"M Luigetti","year":"2015","unstructured":"Luigetti M, Lo Monaco M, Mirabella M, Primiano G, Lucchini M, Monforte M, Servidei S (2015) Oculopharyngeal muscular dystrophy: clinical and neurophysiological features. Clin Neurophysiol 126:2406\u20132408. https:\/\/doi.org\/10.1016\/j.clinph.2015.03.005","journal-title":"Clin Neurophysiol"},{"key":"6251_CR59","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.nmd.2023.09.010","volume":"33","author":"IC Smith","year":"2023","unstructured":"Smith IC, Chakraborty S, Bourque PR, Sampaio ML, Melkus G, Lochmuller H, Woulfe J, Parks RJ, et al. (2023) Emerging and established biomarkers of oculopharyngeal muscular dystrophy. Neuromuscul Disord 33:824\u2013834. https:\/\/doi.org\/10.1016\/j.nmd.2023.09.010","journal-title":"Neuromuscul Disord"},{"key":"6251_CR60","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1038\/s41467-024-49950-2","volume":"15","author":"A Cortese","year":"2024","unstructured":"Cortese A, Beecroft SJ, Facchini S, Curro R, Cabrera-Serrano M, Stevanovski I, Chintalaphani SR, Gamaarachchi H, et al. (2024) A CCG expansion in ABCD3 causes oculopharyngodistal myopathy in individuals of European ancestry. Nat Commun 15:6327. https:\/\/doi.org\/10.1038\/s41467-024-49950-2","journal-title":"Nat Commun"},{"key":"6251_CR61","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1007\/s00415-023-11906-9","volume":"270","author":"N Eura","year":"2023","unstructured":"Eura N, Noguchi S, Ogasawara M, Kumutpongpanich T, Hayashi S, Nishino I (2023) Characteristics of the muscle involvement along the disease progression in a large cohort of oculopharyngodistal myopathy compared to oculopharyngeal muscular dystrophy. J Neurol 270:5988\u20135998. https:\/\/doi.org\/10.1007\/s00415-023-11906-9","journal-title":"J Neurol"},{"key":"6251_CR62","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41467-022-30015-1","volume":"13","author":"HJ Kim","year":"2022","unstructured":"Kim HJ, Mohassel P, Donkervoort S, Guo L, O\u2019Donovan K, Coughlin M,\u00a0Lornage X, Foulds N, et al. (2022) Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat Commun 13:2306. https:\/\/doi.org\/10.1038\/s41467-022-30015-1","journal-title":"Nat Commun"},{"key":"6251_CR63","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1074\/jbc.RA118.007287","volume":"294","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, Phillips BL, Deng Q, Seyfried NT, Pavlath GK, Vest KE, Corbett AH (2019) Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle. J Biol Chem 294:7360\u20137376. https:\/\/doi.org\/10.1074\/jbc.RA118.007287","journal-title":"J Biol Chem"},{"key":"6251_CR64","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.nbd.2004.09.021","volume":"18","author":"P Dion","year":"2005","unstructured":"Dion P, Shanmugam V, Gaspar C, Messaed C, Meijer I, Toulouse A, Laganiere J, Roussel J, et al. (2005) Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis 18:528\u2013536. https:\/\/doi.org\/10.1016\/j.nbd.2004.09.021","journal-title":"Neurobiol Dis"},{"key":"6251_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.986930","volume":"10","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zeuthen C, Zhu C, Wu F, Mezzell AT, Whitlow TJ, Choo HJ, Vest KE (2022) Pharyngeal pathology in a mouse model of oculopharyngeal muscular dystrophy is associated with impaired basal autophagy in myoblasts. Front Cell Dev Biol 10:986930. https:\/\/doi.org\/10.3389\/fcell.2022.986930","journal-title":"Front Cell Dev Biol"},{"key":"6251_CR66","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.otohns.2006.03.015","volume":"135","author":"L Coiffier","year":"2006","unstructured":"Coiffier L, Perie S, Laforet P, Eymard B, St Guily JL (2006) Long-term results of cricopharyngeal myotomy in oculopharyngeal muscular dystrophy. Otolaryngol Head Neck Surg 135:218\u2013222. https:\/\/doi.org\/10.1016\/j.otohns.2006.03.015","journal-title":"Otolaryngol Head Neck Surg"},{"key":"6251_CR67","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44162-023-00020-z","volume":"2","author":"JE Stern","year":"2023","unstructured":"Stern JE, Zvulunov A, Dori A, Charas H, Benyamini L, Ben Simon G, Mentzer L, Greenbaum L, et al. (2023) The National Israeli Registry for Oculo-Pharyngeal Muscular Dystrophy (IsrO-PMD): rationale and design. J Rare Dis 2:16. https:\/\/doi.org\/10.1007\/s44162-023-00020-z","journal-title":"J Rare Dis"},{"key":"6251_CR68","doi-asserted-by":"publisher","first-page":"14848","DOI":"10.1038\/ncomms14848","volume":"8","author":"A Malerba","year":"2017","unstructured":"Malerba A, Klein P, Bachtarzi H, Jarmin SA, Cordova G, Ferry A, Strings V, Polay Espinoza M, et al. (2017) PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 8:14848. https:\/\/doi.org\/10.1038\/ncomms14848","journal-title":"Nat Commun"},{"key":"6251_CR69","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1093\/hmg\/ddz167","volume":"28","author":"A Malerba","year":"2019","unstructured":"Malerba A, Klein P, Lu-Nguyen N, Cappellari O, Strings-Ufombah V, Harbaran S, Roelvink P, Suhy D, et al. (2019) Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1. Hum Mol Genet 28:3301\u20133308. https:\/\/doi.org\/10.1093\/hmg\/ddz167","journal-title":"Hum Mol Genet"},{"key":"6251_CR70","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omtn.2021.02.017","volume":"24","author":"V Strings-Ufombah","year":"2021","unstructured":"Strings-Ufombah V, Malerba A, Kao SC, Harbaran S, Roth F, Cappellari O, Lu-Nguyen N, Takahashi K, et al. (2021) BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy. Mol Ther Nucleic Acids 24:67\u201378. https:\/\/doi.org\/10.1016\/j.omtn.2021.02.017","journal-title":"Mol Ther Nucleic Acids"},{"key":"6251_CR71","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ymthe.2016.10.014","volume":"25","author":"EL van Agtmaal","year":"2017","unstructured":"van Agtmaal EL, Andr\u00e9 LM, Willemse M, Cumming SA, van Kessel IDG, van den Broek WJAA, Gourdon G, Furling D, et al. (2017) CRISPR\/Cas9-induced (CTG\u00b7CAG)n repeat instability in the myotonic dystrophy type 1 locus: implications for therapeutic genome editing. Mol Ther 25:24\u201343. https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.014","journal-title":"Mol Ther"},{"key":"6251_CR72","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.omtn.2017.10.006","volume":"9","author":"C Provenzano","year":"2017","unstructured":"Provenzano C, Cappella M, Valaperta R, Cardani R, Meola G, Martelli F, Cardinali B, Falcone G (2017) CRISPR\/Cas9-mediated deletion of CTG expansions recovers normal phenotype in myogenic cells derived from myotonic dystrophy 1 patients. Mol Ther Nucleic Acids 9:337\u2013348. https:\/\/doi.org\/10.1016\/j.omtn.2017.10.006","journal-title":"Mol Ther Nucleic Acids"},{"key":"6251_CR73","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, et al. (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"6251_CR74","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chi\u00f2 A, Van Damme P, et al. (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387:1099\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2204705","journal-title":"N Engl J Med"},{"key":"6251_CR75","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-1-0716-2772-3_13","volume":"2587","author":"J Stoodley","year":"2023","unstructured":"Stoodley J, Miraz DS, Jad Y, Fischer M, Wood MJA, Varela MA (2023) Peptide-conjugated PMOs for the treatment of myotonic dystrophy. Methods Mol Biol 2587:209\u2013237. https:\/\/doi.org\/10.1007\/978-1-0716-2772-3_13","journal-title":"Methods Mol Biol"},{"key":"6251_CR76","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jcsm.12438","volume":"10","author":"P Harish","year":"2019","unstructured":"Harish P, Malerba A, Lu-Nguyen N, Forrest L, Cappellari O, Roth F, Trollet C, Popplewell L, et al. (2019) Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). J Cachexia Sarcopenia Muscle 10:1016\u20131026. https:\/\/doi.org\/10.1002\/jcsm.12438","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"6251_CR77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/hmg\/ddi422","volume":"15","author":"JE Davies","year":"2006","unstructured":"Davies JE, Sarkar S, Rubinsztein DC (2006) Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 15:23\u201331. https:\/\/doi.org\/10.1093\/hmg\/ddi422","journal-title":"Hum Mol Genet"},{"key":"6251_CR78","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1474-4422(25)00173-5","volume":"24","author":"HEALEY ALS Platform Trial","year":"2025","unstructured":"HEALEY ALS Platform Trial, HEALEY ALS Platform Trial Study Group (2025) Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2\/3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 24:500\u2013511. https:\/\/doi.org\/10.1016\/S1474-4422(25)00173-5","journal-title":"Lancet Neurol"},{"key":"6251_CR79","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/mt.2013.155","volume":"22","author":"S Perie","year":"2014","unstructured":"Perie S, Trollet C, Mouly V, Vanneaux V, Mamchaoui K, Bouazza B, Marolleau JP, Laforet P, et al. (2014) Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I\/IIa clinical study. Mol Ther 22:219\u2013225. https:\/\/doi.org\/10.1038\/mt.2013.155","journal-title":"Mol Ther"},{"key":"6251_CR80","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.molcel.2017.09.033","volume":"68","author":"BS Pinto","year":"2017","unstructured":"Pinto BS, Saxena T, Oliveira R, M\u00e9ndez-G\u00f3mez HR, Cleary JD, Denes LT, McConnell O, Arboleda J, et al. (2017) Impeding transcription of expanded microsatellite repeats by deactivated Cas9. Mol Cell 68:479\u2013490.e5. https:\/\/doi.org\/10.1016\/j.molcel.2017.09.033","journal-title":"Mol Cell"},{"key":"6251_CR81","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm1242","volume":"11","author":"JE Davies","year":"2005","unstructured":"Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O\u2019Donovan DG, Rubinsztein DC (2005) Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 11:672\u2013677. https:\/\/doi.org\/10.1038\/nm1242","journal-title":"Nat Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06251-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06251-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:49:14Z","timestamp":1791949754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-026-06251-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6251"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06251-7","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"9 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy (RebiNeu 186771).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All subjects gave written informed consent covering publication of results in anonymised form; Figs.\n                      \n                      and\n                      \n                      contain no identifiable personal information.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"962"}}